Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-04-27 Declaration of Voting R…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release titled “Bulletin from Annual General Meeting” summarizing the resolutions passed at the AGM (e.g., adoption of financial statements, election of board members, authorizations for share issues and buybacks). It is not the full annual report, nor an investor presentation. It reports the official outcomes of shareholder votes and board decisions at the AGM. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-27 English
Kommuniké från årsstämma i XVIVO Perfusion AB (publ)
AGM Information Classification · 85% confidence The document is a communiqué (press release) summarizing the resolutions and decisions taken at the company’s Annual General Meeting (Årsstämma) on 27 April 2026 — covering approval of financial statements, election of board and auditor, remuneration, incentive program, share issuances, and share buy-back authorizations. It is not the full annual report, nor a mere announcement of publication, but the official minutes/communiqué from the AGM. Therefore it falls under AGM Information (Code: AGM-R).
2026-04-27 Swedish
Preliminary one-year follow-up data from the US PRESERVE trial for XVIVO’s heart technology presented at ISHLT in Toronto
Regulatory Filings Classification · 90% confidence The document is a corporate press release providing preliminary clinical trial results for XVIVO’s investigational heart technology and is made public under the EU Market Abuse Regulation. It is not a financial report (Annual, Interim, Earnings, etc.), nor any other specialized filing category such as Board Changes, M&A, Dividends, or Share Issues. Therefore it falls under the fallback “Regulatory Filings (RNS)” category.
2026-04-22 English
Preliminära ettårsuppföljningsdata från den amerikanska PRESERVE-studien för XVIVOs hjärtteknologi presenterade på ISHLT i Toronto
Regulatory Filings Classification · 78% confidence The document is a press release disclosing preliminary clinical trial follow-up data presented at a medical conference. It is mandatory under the EU Market Abuse Regulation but does not present financial results (so not an Earnings Release or Interim Report), nor is it a management change, capital event, or shareholder vote. It is a general regulatory announcement that does not fit into any of the specialized categories. Therefore, it is classified as a Regulatory Filing (RNS).
2026-04-22 Swedish
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled "XVIVO Perfusion AB (publ) Årsredovisning 2025" which translates to "Annual Report 2025". It contains detailed sections typical of an annual report such as financial highlights, CEO interview, business overview, market information, governance report, financial statements, audit report, and notes. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, management discussion, and strategic information for the fiscal year 2025. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-01 Swedish
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'XVIVO Perfusion AB Årsredovisning 2025' which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report such as financial highlights, management interviews, business overview, market information, governance report, financial statements, audit report, and notes. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial data, strategic discussion, and operational review for the fiscal year 2025. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-01 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.